EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims against Aerie Pharmaceuticals, Inc.

The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) resulting from allegations that Aerie may have issued materially misleading business information to the investing public.

On April 23, 2015, after markets closed, Aerie announced that its Rhopressa drug candidate failed to achieve its primary efficacy endpoint of non-inferiority to (no worse than) timolol in its recent drug trial. On this news, shares of Aerie fell $22.52 per share or over 60% to close at $12.87 per share on April 24, 2015.

The Rosen Law Firm is investigating a class action lawsuit to recover losses suffered by Aerie investors. If you purchased shares of Aerie on or before April 23, 2015, please visit the firm’s website at http://rosenlegal.com/cases-588.html for more information. You may also contact Phillip Kim, Esq. or Jonathan Horne, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or jhorne@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.